Association of immune-related adverse events and outcomes in kidney cancer

Previous studies have shown that cancer patients who experience immune-related side effects (immune-related adverse events) when treated with immunotherapy may have a better response to treatment. This study looks at this effect in patients with metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (immunotherapy). In the study, 43 patients with metastatic RCC were […]

read more

Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival

A recent study published in JAMA Network Open looked at the data from over 10,000 renal cell carcinoma (RCC) patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and reported on the sites of metastases for three of the RCC subtypes and their survival outcomes. Metastases from clear cell RCC (9252 patients, 92%) […]

read more

Most coronavirus-positive cancer patients are asymptomatic

Most studies have shown that many cancer patients are at high risk of developing severe forms of COVID-19. In a study of nearly 900 cancer patients with coronavirus in the UK, for instance, the death rate was estimated to be 33.6%, which is much higher than the general population. However, most of these patients were […]

read more

Pazopanib for poor risk kidney cancer patients

Pazopanib is used for first-line metastatic RCC treatment, but the data for poor-risk patients are scarce. The FLIPPER study was designed to determine the safety and efficacy of first-line pazopanib in poor-risk patients with metastatic RCC. FLIPPER was a single-arm, open-label, phase IV trial involving 60 patients with poor-risk metastatic mRCC. All patients were treated […]

read more

Partial nephrectomy for patients with rare Xp11.2 translocation kidney cancer

XP11.2 translation renal cell carcinoma (RCC) is a very rare and aggressive subtype of RCC. Currently, partial nephrectomy can be used for treating kidney cancer at an early stage (T1a and T1b stage). Although partial nephrectomy can remove primary kidney tumours completely, there is always a risk of the tumour coming back because not all […]

read more

COVID-19 outcomes with anticancer treatments

There is a lot of ongoing research to understand the effect of cancer and its treatment on the outcomes of patients who contract COVID-19. Cancer patients could be at greater risk from COVID-19 because their immune systems are suppressed or they have other conditions due to their cancer or its treatment. Cancer patients are also […]

read more

Impact of delay in surgery or time to surgery on kidney cancer outcomes

A recent study published in the Journal of Urology this month looked at the waiting times from diagnosis to surgery and the impact this had on outcomes for kidney cancer patients. The time from diagnosis of a kidney tumour to removal of the tumour during surgery can be very worrying for patients and clinicians due […]

read more

The effect of age and gender on outcomes in kidney cancer

In this interview, Dr Rana McKay discusses the impact of age and gender on the outcomes of patients with renal cell carcinoma (RCC) who are receiving targeted treatment options and the implications of these findings for individualised care. She also touches upon the influence of age and gender on the toxicity of systemic treatments and […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

Challenges of early detection of renal cell carcinoma

The incidence of kidney cancer in the UK has risen by 47% over the past decade, with 12 000 new cases in 2015. Diagnosing patients with kidney cancer can be challenging. The majority of kidney cancers are renal cell carcinomas (RCCs), which make up about 85% of kidney cancers. Signs and symptoms of RCC are […]

read more
Showing 1 to 10 of 37 results
  TOP